fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

EHA 2018: The Issue of Frailty in MM

Written by | 24 Jun 2018

When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.

EHA 2018: Preferred treatment combinations and sequencing in transplant eligible and elderly MM patients

Written by | 24 Jun 2018

The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.

BSH 2018: Hodgkin lymphoma: tackling treatment challenges in the older patient

Written by | 21 Jun 2018

Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.

ASH 2017 Highlights

Written by | 5 Feb 2018

Professor Anas Younes (MSKCC, New York), Professor John Radford (Manchester) and Dr Graham Collins (Oxford). Interviews by Esther Drain. Once again ASH provided much food for thought and above leading experts discuss their… read more.

BSH 2017: How I treat molecular high-risk myeloma – what can we do, what should we do?

Written by | 6 Apr 2017

High-risk multiple myeloma (MM) continues to pose a challenge to haematologists both in terms of diagnostics and therapy. Opening the UK Myeloma Forum at the 2017 BSH annual… read more.

Vulnerable patients: burning questions in IBD

Written by | 30 Mar 2017

An interesting session at ECCO dealt with the patients for whom there is sparce data to guide their treatment – experts in the field gave their guidance to… read more.

EHA 2016: Managing multiple myeloma in elderly/frail patients. Professor Antonio Palumbo (University of Torino, Italy) discusses the impact of age on outcomes (abstract E1295) and Professor Roman Hajek (University of Ostrava, Czech Republic) talks about preferred therapeutic strategies for elderly MM patients.

Written by | 20 Jul 2016

Managing multiple myeloma in elderly/frail patients   Although multiple myeloma is a disease of old age, elderly patients vary a great deal in terms of fitness and ability… read more.

EHA 2016: Preventing clonal evolution in multiple myeloma – evidence from clinical trials. Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution in multiple myeloma (MM) and summarised the latest clinical data.

Written by | 19 Jul 2016

Preventing clonal evolution in multiple myeloma – evidence from clinical trials by Maria Dalby Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution… read more.

EHA 2016: How monoclonal antibodies will change the treatment of multiple myeloma. Professor Antonio Palumbo (Torino, Italy) discuss the results of the CASTOR trial and Professor Meletios-Athanasios Dimopoulos (Athens, Greece) discussing POLLUX.

Written by | 15 Jul 2016

How monoclonal antibodies will change the treatment of multiple myeloma  by Maria Dalby   Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Meletios Dimopoulos, University of Athens School of… read more.

ASCO 2016: Elderly glioblastoma patients achieve longer survival with radiation plus temozolomide

Written by | 5 Jul 2016

by Bruce Sylvester: Researchers from a randomized phase III trial report that addition of temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide,… read more.

ASCO 2016: Previously untreatable advanced bladder cancer patients respond to immunotherapy

Written by | 4 Jul 2016

by Bruce Sylvester: Anti-PD-L1 immunotherapy atezolizumab (TECENTRIQ) has shown efficacy in previously untreated patients with advanced bladder cancer who are ineligible for standard treatment with cisplatin.

World Health Matters: Sweden: Improved lifestyle led to decreased cholesterol and less cardiac death

Written by | 24 Jun 2016

by Gary Finnegan: Cholesterol levels – the most common risk factor for heart attacks – have decreased in northern Sweden over the last 20 years. Since medication only… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.